PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil

PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil

Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melan...

Full description

Bibliographic Details
Main Authors: Bruna Pereira Sorroche, Renan de Jesus Teixeira, Caio Augusto Dantas Pereira, Iara Viana Vidigal Santana, Lazar Vujanovic, Vinicius de Lima Vazquez, Lidia Maria Rebolho Batista Arantes
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Diagnostics
Subjects:
melanoma
immune checkpoint blockade
response
PD-L1 expression
Online Access:https://www.mdpi.com/2075-4418/13/6/1041

Internet

https://www.mdpi.com/2075-4418/13/6/1041

Similar Items